Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sara Mainardi
Observed names:
Mainardi, Sara,
S Mainardi,
S. Mainardi
Institution:
The Netherlands Cancer Institute
Observed institutions:
Johns Hopkins University,
The Netherlands Cancer Institute,
Spanish National Cancer Research Centre,
Oncode Institute,
Cancer Genomics Centre,
Instituto Nazionale Tumori Regina Elena
show all 6
ORCID:
0000-0001-7255-6153
Observed ORCID:
0000-0001-7255-6153
OpenAlex ID:
A5005545073
Inducing and exploiting vulnerabilities for the treatment of liver cancer
2019
·
Cun Wang
, Serena Vegna
, et al.
·
Nature
·
454
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
2018
·
Sara Mainardi
, Antonio Mulero-Sánchez
, et al.
·
Nature Medicine
·
339
High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer
2017
·
Liqin Wang
, Rodrigo Leite de Oliveira
, et al.
·
Cell Reports
·
240
Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma
2013
·
Sara Mainardi
, Nieves Mijimolle
, et al.
·
Proceedings of the National Academy of Sciences
·
181
PDF
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility
2016
·
Loredana Vecchione
, Valentina Gambino
, et al.
·
Cell
·
97
PDF
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
2023
·
Joris van de Haar
, Xuhui Ma
, et al.
·
Nature Medicine
·
96
PDF
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes
2009
·
S Careccia
, S Mainardi
, et al.
·
Oncogene
·
86
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
2024
·
Matheus Henrique Dias
, Anoek Friskes
, et al.
·
Cancer Discovery
·
67
PDF
Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse
2024
·
Mengnuo Chen
, Sara Mainardi
, et al.
·
Cell Reports Medicine
·
52
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer
2022
·
Katrin J. Frank
, Antonio Mulero-Sánchez
, et al.
·
Cell Reports Medicine
·
49
PDF
Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines
2017
·
Marion A.A. Libouban
, Jeroen A.D.M. de Roos
, et al.
·
Oncotarget
·
37
PDF
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers
2024
·
Robin A. Jansen
, Sara Mainardi
, et al.
·
Proceedings of the National Academy of Sciences
·
25
PDF
A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells
2018
·
Anna Ressa
, Evert Bosdriesz
, et al.
·
Molecular & Cellular Proteomics
·
18
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma
2023
·
Antonio Mulero‐Sánchez
, Christel F. A. Ramirez
, et al.
·
Molecular Oncology
·
16
PDF
ΔN-p73 is a transcriptional target of the PML/RARα oncogene in myeloid differentiation
2007
·
S Mainardi
, A Pelosi
, et al.
·
Cell Death and Differentiation
·
10
A large-scale organoid-based screening platform to advance drug repurposing in pancreatic cancer
2022
·
Sara Mainardi
, Rene Bernards
·
Cell Genomics
·
9
PDF
CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer
2026
·
Antonio Mulero-Sánchez
, Astrid Bosma
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
8
With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors
2023
·
Sara Mainardi
·
Cell Reports Medicine
·
8
PDF
The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer
2026
·
Ashwini C. Kanhailal
, Jonathan E. Knikman
, et al.
·
European Journal of Cancer
·
3
Codon-specific KRAS mutations predict overall survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
2022
·
Joris van de Haar
, Xuhui Ma
, et al.
·
Journal of Clinical Oncology
·
3
1630P Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
2023
·
A.C. Kanhailal
, A. Mulero-Sánchez
, et al.
·
Annals of Oncology
·
2
PDF
Data from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
2024
·
Matheus Henrique Dias
, Anoek Friskes
, et al.
·
1
Figure S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
2026
·
Matheus Henrique Dias
, Anoek Friskes
, et al.
Figure S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
2026
·
Matheus Henrique Dias
, Anoek Friskes
, et al.
Figure S8 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
2026
·
Matheus Henrique Dias
, Anoek Friskes
, et al.
Show more works
View as search
Works count:
79
Citation count:
1,801
H-index:
14
I10-index:
15
Year
Topic
Type